DK2229407T3 - Nye insulinderivater med ekstremt forsinket tids-/virkningsprofil - Google Patents
Nye insulinderivater med ekstremt forsinket tids-/virkningsprofil Download PDFInfo
- Publication number
- DK2229407T3 DK2229407T3 DK09701358.5T DK09701358T DK2229407T3 DK 2229407 T3 DK2229407 T3 DK 2229407T3 DK 09701358 T DK09701358 T DK 09701358T DK 2229407 T3 DK2229407 T3 DK 2229407T3
- Authority
- DK
- Denmark
- Prior art keywords
- arg
- glu
- asp
- lys
- exendin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 169
- 230000000694 effects Effects 0.000 title claims description 20
- 230000003111 delayed effect Effects 0.000 title description 10
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 134
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 121
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 107
- 239000004026 insulin derivative Substances 0.000 claims description 87
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 83
- 108010011459 Exenatide Proteins 0.000 claims description 78
- 229960001519 exenatide Drugs 0.000 claims description 75
- 102000004877 Insulin Human genes 0.000 claims description 70
- 108090001061 Insulin Proteins 0.000 claims description 70
- 108010066381 preproinsulin Proteins 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 50
- 239000002243 precursor Substances 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 44
- 229940125396 insulin Drugs 0.000 claims description 40
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 claims description 25
- 239000011701 zinc Substances 0.000 claims description 18
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 17
- 229910052725 zinc Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000126 substance Chemical group 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- SSAAJZQUEUTACT-MDBKHZGBSA-N exendin 2 Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 SSAAJZQUEUTACT-MDBKHZGBSA-N 0.000 claims description 4
- 108010028997 heliodermin Proteins 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims description 3
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 3
- 239000013011 aqueous formulation Substances 0.000 claims description 3
- 108010015174 exendin 3 Proteins 0.000 claims description 3
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 125000002642 gamma-glutamyl group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 148
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 119
- 239000013612 plasmid Substances 0.000 description 116
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 114
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 74
- 108020004414 DNA Proteins 0.000 description 71
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 70
- 238000010276 construction Methods 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 40
- 230000009435 amidation Effects 0.000 description 36
- 238000007112 amidation reaction Methods 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 230000009471 action Effects 0.000 description 29
- 239000000047 product Substances 0.000 description 26
- HKXLAGBDJVHRQG-YFKPBYRVSA-N L-lysinamide Chemical compound NCCCC[C@H](N)C(N)=O HKXLAGBDJVHRQG-YFKPBYRVSA-N 0.000 description 21
- 101150102573 PCR1 gene Proteins 0.000 description 21
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000007792 addition Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
- 230000010030 glucose lowering effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- 235000013922 glutamic acid Nutrition 0.000 description 9
- 239000004220 glutamic acid Substances 0.000 description 9
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- 108010076181 Proinsulin Proteins 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000011592 zinc chloride Substances 0.000 description 7
- 235000005074 zinc chloride Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- 102100040918 Pro-glucagon Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108010075254 C-Peptide Proteins 0.000 description 4
- 108010057186 Insulin Glargine Proteins 0.000 description 4
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- -1 Apidra® Chemical compound 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 229960002869 insulin glargine Drugs 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000001019 normoglycemic effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 2
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 108700007397 Arg(B31)- insulin Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 108010065691 Biphasic Insulins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- WEDIKSVWBUKTRA-WTKGVUNUSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC WEDIKSVWBUKTRA-WTKGVUNUSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000196319 Chlorophyceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
- MKIAPEZXQDILRR-YUMQZZPRSA-N Gly-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN MKIAPEZXQDILRR-YUMQZZPRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- LJUIEESLIAZSFR-SRVKXCTJSA-N His-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N LJUIEESLIAZSFR-SRVKXCTJSA-N 0.000 description 1
- CUEQQFOGARVNHU-VGDYDELISA-N His-Ser-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUEQQFOGARVNHU-VGDYDELISA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 1
- LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- MHNBYYFXWDUGBW-RPTUDFQQSA-N Phe-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O MHNBYYFXWDUGBW-RPTUDFQQSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000592344 Spermatophyta Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- FQNUWOHNGJWNLM-QWRGUYRKSA-N Tyr-Cys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FQNUWOHNGJWNLM-QWRGUYRKSA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 108700025974 depot- insulin Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (33)
1. Insulinanalogon med formel I
idet AO repræsenterer Arg; A5 repræsenterer Asp, Gin eller Glu; A15 repræsenterer Asp, Glu eller Gin; A18 repræsenterer Asp, Glu eller Asn; B-l repræsenterer Asp, Glu eller en aminogruppe; BO repræsenterer Asp, Glu eller en kemisk binding; Bl repræsenterer Asp, Glu eller Phe; B2 repræsenterer Asp, Glu eller Val; B3 repræsenterer Asp, Glu eller Asn; B4 repræsenterer Asp, Glu eller Gin; B29 repræsenterer Lys; B30 repræsenterer Thr; B31 repræsenterer Arg eller Lys; B32 repræsenterer Arg-NH2 eller Lys-NH2 idet to aminosyrerester fra gruppen indeholdende A5, A15, A18, B-l, BO, Bl, B2, B3 og B4 samtidigt og uafhængigt af hinanden repræsenterer Asp eller Glu.
2. Insulinanalogon ifølge et eller flere af de foregående krav, idet A5 repræsenterer Glu.
3. Insulinanalogon ifølge et eller flere af de foregående krav, idet A15 repræsenterer Glu.
4. Insulinanalogon ifølge et eller flere af de foregående krav, idet A18 repræsenterer Asp.
5. Insulinanalogon ifølge et eller flere af de foregående krav, idet B-l repræsenterer en aminogruppe.
6. Insulinanalogon ifølge et eller flere af de foregående krav, idet BO repræsenterer Glu.
7. Insulinanalogon ifølge et eller flere af de foregående krav, idet Bl repræsenterer Asp.
8. Insulinanalogon ifølge et eller flere af de foregående krav, idet B2 repræsenterer Val.
9. Insulinanalogon ifølge et eller flere af de foregående krav, idet B3 repræsenterer Asp.
10. Insulinanalogon ifølge et eller flere af de foregående krav, idet B4 repræsenterer Glu.
11. Insulinanalogon ifølge et eller flere af de foregående krav udvalgt af en gruppe indeholdende: Arg (AO), His (A8), Glu (A5), Asp (A18), Gly (A21), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5), Asp (A18), Gly (A21), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15) , Asp (A18) , Gly (A21), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15) , Asp (A18) , Gly (A21), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu(A5), Glu (A15), Gly (A21), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5), Glu (A15), Gly (A21), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His(A8), Glu (A5), Gly (A21), Asp (B3) , Arg (B31) , Arg (B32) - NH2 humaninsulin, Arg (AO), His(A8), Glu (A5), Gly (A21) , Asp (B3) , Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Asp (B3) , Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Asp (B3), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Asp (B3) , Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His(A8), Gly (A21), Asp (B3) , Glu (B4) , Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Gly (A21), Asp (B3), Glu (B4), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5) , Gly (A21), Glu (B4), Arg (B31) , Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5) , Gly (A21), Glu (B4), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Glu (B4), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Glu (B4), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Glu (B4), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Glu (B4), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5) , Gly (A21), Glu (BO), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5) , Gly (A21), Glu (BO), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15) , Gly (A21), Glu (BO), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Glu (BO), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Glu (BO), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (Al8),Gly (A21), Glu (BO), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5), Gly (A21), Asp (Bl), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A5) , Gly (A21), Asp (Bl), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Asp (Bl), Arg (B31), Arg(B32) - NH2 humaninsulin, Arg (AO), His (A8), Glu (A15), Gly (A21), Asp (Bl), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Asp (Bl), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Asp (Bl), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Gly (A21), Glu (BO), Asp (Bl), Arg (B31), Arg (B32) - NH2 humaninsulin, Arg (AO), His (A8), Gly (A21), Glu (BO), Asp (Bl), Arg (B31), Lys (B32) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B30), Arg (B31) - NH2 humaninsulin, Arg (AO), His (A8), Asp (A18), Gly (A21), Asp (B3), Arg (B30), Lys (B31) - NH2 humaninsulin.
12. Fremgangsmåde til fremstilling af et insulinanalogon ifølge et af kravene 1 til 11, idet der rekombinant fremstilles en forløber af insulinanalogonet, forløberen enzymatisk processeres til dobbeltkædet insulin, og der gennemføres en kobling med argininamid i nærvær af et enzym med trypsinaktivitet, og insulinanalogonet isoleres.
13. Anvendelse af et insulinanalogon ifølge et af kravene 1 til 11 til fremstilling af et medikament til behandling af diabetes mellitus.
14. Anvendelse af et insulinanalogon ifølge et af kravene 1 til 11 i en fremgangsmåde til fremstilling af et medikament til behandling af diabetes mellitus type I eller type II eller til terapeutisk understøttelse af beta-celleregenerationen.
15. Lægemiddel indeholdende et insulinanalog ifølge et af kravene 1 til 11 og/eller fysiologisk forligelige salte heraf.
16. Formulering af insulinanalogonet ifølge et af kravene 1 til 11, idet formuleringen foreligger i vandig form indeholdende det opløste insulinanalogon.
17. Formulering af insulinanalogonet ifølge et af kravene 1 til 11, idet formuleringen foreligger i form af pulver.
18. Formulering ifølge krav 17, idet insulinanalogonet ifølge et af kravene 1 til 11 er indeholdt i krystallin og/eller amorf form.
19. Formulering af insulinanalogonet ifølge et af kravene 1 til 11, idet formuleringen foreligger i form af en suspension.
20. Formulering af insulinanalogonet ifølge et af kravene 1 til 11, idet formuleringen desuden indeholder en kemisk chaperon.
21. DNA kodende for en præ-proinsulin af et insulinanalogon ifølge et af kravene 1 til 11.
22. Vektor indeholdende et DNA ifølge krav 21.
23. Ikke-human værtsorganisme indeholdende et DNA ifølge krav 21 eller en vektor ifølge krav 22.
24. Formulering ifølge et eller flere af kravene 16 til 20, hvori der endvidere også er indeholdt et glucagon-lignende peptid-1 (GLP1) eller et analogon eller derivat heraf eller exendin-3 eller -4 eller et analogon eller derivat heraf.
25. Formulering ifølge krav 24, hvori der endvidere er indeholdt exendin-4.
26. Formulering ifølge krav 24, hvori et analogon af exendin-4 udvælges af en gruppe indeholdende H-desPro36-exendin-4-Lys6-NH2, H-des (Pro36'37) -exendin-4-Lys4-NH2 og H-des (Pro36'37)-exendin-4-Lys5_NH2, eller et farmakologisk acceptabelt salt heraf.
27. Formulering ifølge krav 24, hvori et analogon af exendin-4 udvælges af en gruppe indeholdende desPro36 [Asp28] exendin-4 (1-39), desPro36 [IsoAsp28] exendin-4 (1-39), desPro36 [Met (O)14, Asp23] exendin-4 (1-39), desPro36 [Met (O)14, IsoAsp28] exendin-4 (1-39), desPro36 [Trp(02)25 Asp28] exendin-2 (1-39), desPro36 [Trp(02) 25, IsoAsp28] exendin-2 (1-39), desPro36 [Met (O) 14Trp (O2)25, Asp28] exendin-4 (1-39) og desPro36 [Met (0) 14Trp (02) 25, IsoAsp28] exendin-4 (1-39), eller et farmakologisk acceptabelt salt heraf.
28. Formulering ifølge krav 27, hvori der på C-terminiene af analoger af exendin-4 er tilføjet peptidet -Lys6-NH2.
29. Formulering ifølge krav 24, hvori der udvælges et analogon af exendin-4 af en gruppe indeholdende H-(Lys)6- des Pro36 [Asp28] exendin-4 (1-39)-Lys6-NH2 des Asp28Pro36, Pro37, Pro38 exendin-4 (1-39) -NH2, H-(Lys)6- des Pro36, Pro37, Pro38 [Asp28] exendin-4 (1-39) -NH2, H-Asn-(Glu) 5 des Pro36, Pro37, Pro38 [Asp28] exendin-4 (1-39) -NH2, des Pro35, Pro37, Pro38 [Asp28] exendin-4 (1-39) - (Lys) 6~NH2, H-(Lys)6- des Pro36, Pro37, Pro33 [Asp28] exendin-4 (1-39) - (Lys) 6-NH2, H-Asn-(Glu) b- des Pro36, Pro37, Pro38 [Asp28] exendin-4 (1-39)-(Lys) 6-NH2, H- (Lys) s- des Pro36 [Trp(02) 25, Asp28] exendin-4 (1-39)-Lys6-NH2, H- des Asp28 Pro36, Pro37, Pro38 [Trp (02)2S] exendin-4 (l-39-NH2, H- (Lys) 6- des Pro36, Pro37, Pro38 [Trp(02) 25, Asp28] exendin-4 (1-
39) -NH2, H-Asn-(Glu) 5- des Pro36, Pro37, Pro38 [Trp(02) 25, Asp28] exendin-4(1-39) -NH2, des Pro36, Pro37, Pro38 [Trp(02) 25, Asp28] exendin-4 (1-39) - (Lys) 6-NH2, H- (Lys) 6- des Pro36, Pro37, Pro38 [Trp(02) 25, Asp28] exendin-4 (1- 39) - (Lys) 5-NH2, H-Asn-(Glu) 5- des Pro36, Pro37, Pro38 [Trp(02) 25, Asp28] exendin-4 (1-39) - (Lys) S-NH2, H- (Lys) 6- des Pro36 [Met (O)14, Asp28] exendin-4 (1-39)-Lys6-NH2, des Met (O)14 Asp28 Pro36, Pro37, Pro38 exendin-4 (1-39) -NH2, H-(Lys)6- des Pro36, Pro37, Pro38 [Met (O)14, Asp28] exendin-4 (1-39) -NH2, H-Asn-(Glu) 5- des Pro36, Pro37, Pro38 [Met (O)14, Asp28] exendin-4(1-39) -NH2, des Pro36, Pro37, Pro38 [Met (O)14, Asp28] exendin-4 (1-39) - (Lys) 6-NH2, H-(Lys)6- des Pro36, Pro37, Pro38 [Met (O)14, Asp28] exendin-4 (1-39) -Lys6-NH2, H-Asn-(Glu) s des Pro36, Pro37, Pro38 [Met (O)14, Asp28] exendin-4(1-39)-(Lys)6-NH2, H-(Lys)6~ des Pro36 [Met (O)14, Trp(02) 25, Asp28] exendin-4 (1-39) - LyS6-NH2, des Asp28 Pro36, Pro37, Pro38 [Met (O)14, Trp (02) 25] exendin-4 (1-39)-NH2, H-(Lys)6- des Pro36, Pro37, Pro38 [Met (O)14, Trp(02) 25, Asp28] exendin-4 (1-39) -NH2, H-Asn-(Glu) 5- des Pro36, Pro37, Pro38 [Met (O)14, Asp28] exendin-4(1-39) -NH2, des Pro36, Pro37, Pro38 [Met (O)14, Trp(02) 25, Asp28] exendin-4 (1- 39) - (Lys) 5-NH2, H-(Lys)6- des Pro36, Pro37, Pro38 [Met (O)14, Trp(02) 25, Asp28] exendin-4 (1-39) - (Lys) 6-NH2, H-Asn-(Glu) b- des Pro36, Pro37, Pro38 [Met (O)14, Trp(02) 25, Asp28] exendin-4 (1-39) - (Lys) 6-NH2, eller et farmakologisk acceptabelt salt heraf.
30. Formulering ifølge krav 24, hvori der endvidere er indeholdt Arg34, Lys26 (Νε (γ-glutamyl (Na-hexadecanoyl) ) ) GLP-1 (7-37) [liraglutider] eller et farmakologisk acceptabelt salt heraf.
31. Vandig formulering af insulinanalogonet ifølge et af kravene 1 til 11, som indeholder ingen eller mindre end 15 pg/ml zink.
32. Vandig formulering af insulinanalogonet ifølge et af kravene 1 til 11, som indeholder ingen eller mindre end 15 yg/ml til 2 mg/ml zink.
33. Formulering ifølge krav 32, idet der er indeholdt 200 yg/ml zink.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200810003568 DE102008003568A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
US4465908P | 2008-04-14 | 2008-04-14 | |
DE200810025008 DE102008025008A1 (de) | 2008-05-24 | 2008-05-24 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
PCT/EP2009/000017 WO2009087081A2 (de) | 2008-01-09 | 2009-01-06 | Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2229407T3 true DK2229407T3 (da) | 2017-02-27 |
Family
ID=40568276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09701358.5T DK2229407T3 (da) | 2008-01-09 | 2009-01-06 | Nye insulinderivater med ekstremt forsinket tids-/virkningsprofil |
Country Status (32)
Country | Link |
---|---|
US (1) | US9644017B2 (da) |
EP (1) | EP2229407B1 (da) |
JP (1) | JP5694779B2 (da) |
KR (1) | KR20100111682A (da) |
CN (1) | CN102007143B (da) |
AR (1) | AR070118A1 (da) |
AU (1) | AU2009203809B2 (da) |
BR (1) | BRPI0907371A2 (da) |
CA (1) | CA2711749A1 (da) |
CL (1) | CL2009000017A1 (da) |
CO (1) | CO6311108A2 (da) |
DK (1) | DK2229407T3 (da) |
DO (1) | DOP2010000209A (da) |
EC (1) | ECSP10010333A (da) |
ES (1) | ES2613152T3 (da) |
GT (1) | GT201000199A (da) |
HK (1) | HK1149772A1 (da) |
HU (1) | HUE030537T2 (da) |
IL (1) | IL206844A (da) |
MA (1) | MA31998B1 (da) |
MY (1) | MY152979A (da) |
NI (1) | NI201000114A (da) |
NZ (1) | NZ586590A (da) |
PA (1) | PA8811601A1 (da) |
PE (1) | PE20091377A1 (da) |
PL (1) | PL2229407T3 (da) |
RU (1) | RU2524423C2 (da) |
TN (1) | TN2010000298A1 (da) |
TW (1) | TW200942256A (da) |
UY (1) | UY31596A1 (da) |
WO (1) | WO2009087081A2 (da) |
ZA (1) | ZA201003926B (da) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005046113A1 (de) * | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
EP2074140B8 (en) | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
EP2229407B1 (de) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
CN101970476B (zh) | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的胰岛素衍生物 |
US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
BRPI0911571A2 (pt) * | 2008-04-22 | 2018-04-03 | Univ Case Western Reserve | método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira |
US9200053B2 (en) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
KR20120129875A (ko) | 2008-07-31 | 2012-11-28 | 케이스 웨스턴 리저브 유니버시티 | 염소화 아미노산을 갖는 인슐린 유사체 |
RS59913B1 (sr) * | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
CA2747109A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
MX2011006315A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
MY159865A (en) * | 2009-07-06 | 2017-02-15 | Sanofi Aventis Deutschland | Aqueous insulin preparations containing methionine |
WO2011003820A1 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Hitze- und schüttelstabile insulinzubereitungen |
WO2011003823A1 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Langsamwirkende insulinzubereitungen |
EA022816B1 (ru) | 2009-07-13 | 2016-03-31 | Зилэнд Фарма А/С | Ацилированные аналоги глюкагона |
US8399407B2 (en) | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
ES2534191T3 (es) * | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
SG181527A1 (en) | 2009-12-11 | 2012-07-30 | Univ Case Western Reserve | Insulin analogues with chlorinated amino acids |
WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
CN102933599A (zh) * | 2010-06-23 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 包含额外的二硫键的人胰岛素 |
EP3366304B1 (en) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Diabetes therapy |
SG186764A1 (en) | 2010-06-24 | 2013-02-28 | Zealand Pharma As | Glucagon analogues |
BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
JP2014504597A (ja) | 2011-01-20 | 2014-02-24 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体とインスリン類似体の組合せ物 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
PL2750699T3 (pl) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
EP2768520A4 (en) * | 2011-10-18 | 2015-07-15 | AmideBio LLC | CHEMICALLY AND THERMODYNAMICALLY STABLE INSULIN ANALOGUES AND IMPROVED PRODUCTION METHODS THEREFOR |
SG11201407137PA (en) | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AR094181A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
EP2986315A4 (en) | 2013-04-17 | 2017-03-01 | AmideBio LLC | Chemically and thermodynamically stable insulin analogues and improved methods for their production |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MY176022A (en) | 2013-10-17 | 2020-07-21 | Boehringer Ingelheim Int | Acylated glucagon analogues |
KR102310389B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 효능제 화합물 및 방법 |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
KR20160101195A (ko) | 2014-01-09 | 2016-08-24 | 사노피 | 인슐린 아스파트의 안정화된 약제학적 제형 |
SG11201604710XA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
MA39301A1 (fr) | 2014-01-20 | 2018-01-31 | Hanmi Pharmaceutical Co Ltd | Insuline à action prolongée et utilisation associée |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
BR112017004544A2 (pt) | 2014-10-06 | 2018-01-23 | Univ Case Western Reserve | insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus |
DK3212218T3 (da) | 2014-10-29 | 2021-08-30 | Zealand Pharma As | GIP-agonistforbindelser og fremgangsmåder |
HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
RU2764197C1 (ru) | 2016-09-23 | 2022-01-14 | Ханми Фарм. Ко., Лтд. | Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение |
BR112019019823A2 (pt) | 2017-03-23 | 2020-04-22 | Hanmi Pharm Ind Co Ltd | conjugado, composição farmacêutica para prevenir ou tratar diabetes e método para tratamento de diabetes |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3984696A (en) | 1974-12-11 | 1976-10-05 | Medi-Ray, Inc. | Radiation guard for X-ray table |
JPS6033474B2 (ja) | 1978-05-11 | 1985-08-02 | 藤沢薬品工業株式会社 | 新規なヒアルロニダ−ゼbmp−8231およびその製造法 |
DK113585D0 (da) * | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
DK347086D0 (da) * | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
DE3880346T2 (de) | 1987-02-25 | 1993-07-29 | Novo Nordisk As | Insulinderivate. |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
US4923162A (en) | 1988-09-19 | 1990-05-08 | Fleming Matthew C | Radiation shield swivel mount |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US5225323A (en) * | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
US5006718A (en) | 1989-07-21 | 1991-04-09 | Lenhart Mark J | X-ray shield for X-ray examination table |
IL95495A (en) | 1989-08-29 | 1996-10-16 | Hoechst Ag | Fusion proteins their preparation and use |
DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
DK10191D0 (da) * | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
YU18596A (sh) | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
JPH11292787A (ja) | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE19637230A1 (de) | 1996-09-13 | 1998-03-19 | Boehringer Mannheim Gmbh | Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
WO1997048413A1 (en) | 1996-06-20 | 1997-12-24 | Novo Nordisk A/S | Insulin preparations containing carbohydrates |
ATE356830T1 (de) | 1996-08-30 | 2007-04-15 | Novo Nordisk As | Glp-1 derivate |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
DE19735711C2 (de) | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
US6444641B1 (en) * | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
IL134901A0 (en) * | 1997-10-24 | 2001-05-20 | Lilly Co Eli | Insoluble insulin compositions |
US5981964A (en) | 1997-12-22 | 1999-11-09 | Bruce J. McAuley | Adjustable X-ray shield and on-line dosimetry system using same |
DE69924232D1 (de) | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
TR200003048T2 (tr) | 1998-02-23 | 2000-12-21 | Neurocrine Biosciences, Inc. | İnsülinin peptit analoglarının diyabet tedavisi için kullanımı. |
AU762626B2 (en) | 1998-06-05 | 2003-07-03 | Nutrinia Ltd | Insulin supplemented infant formula |
JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2007204498A (ja) | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
DE19947456A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
BR0014486A (pt) | 1999-10-04 | 2002-09-17 | Chiron Corp | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
JP4855640B2 (ja) * | 2001-04-02 | 2012-01-18 | ノヴォ ノルディスク アー/エス | インシュリン前駆体及びその調製方法 |
WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
JP2005519041A (ja) | 2001-12-20 | 2005-06-30 | イーライ・リリー・アンド・カンパニー | 長期作用を備えたインスリン分子 |
AU2002351756A1 (en) | 2001-12-21 | 2003-07-15 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
AU2003243929B2 (en) | 2002-07-04 | 2009-06-04 | Zp Holding Spv K/S | GLP-1 and methods for treating diabetes |
PL377591A1 (pl) | 2002-10-02 | 2006-02-06 | Zealand Pharma A/S | Stabilizowane związki eksendyny-4 |
CA2518776A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
DE10325567B4 (de) | 2003-06-05 | 2008-03-13 | Mavig Gmbh | Strahlenschutzanordnung mit separierbarer Umhüllung |
WO2005046716A1 (en) | 2003-11-13 | 2005-05-26 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
US20080248999A1 (en) | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
WO2006029634A2 (en) | 2004-09-17 | 2006-03-23 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
US20090142338A1 (en) | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
PT1926749E (pt) | 2005-09-14 | 2011-09-29 | Sanofi Aventis Deutschland | Clivagem de precursores de insulinas por uma variante de tripsina |
KR101105871B1 (ko) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
WO2007081824A2 (en) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
KR101374851B1 (ko) | 2006-01-10 | 2014-03-14 | 톰슨 라이센싱 | 4:4:4 코딩의 병렬 구현을 위한 방법 및 장치 |
US20070191271A1 (en) | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
EP1986674A4 (en) | 2006-02-13 | 2009-11-11 | Nektar Therapeutics | PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME |
US7763582B2 (en) | 2006-02-21 | 2010-07-27 | University Of Medicine And Dentistry Of New Jersey | Localized insulin delivery for bone healing |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
PT2074141T (pt) | 2006-09-22 | 2016-11-10 | Novo Nordisk As | Análogos de insulina resistentes a proteases |
CN101715340A (zh) | 2007-04-23 | 2010-05-26 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
WO2008145323A1 (en) | 2007-05-31 | 2008-12-04 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for interferons |
US9173991B2 (en) | 2007-07-02 | 2015-11-03 | Roche Diabetes Care, Inc. | Device for drug delivery |
PL2219607T3 (pl) | 2007-11-01 | 2012-12-31 | Merck Serono Sa | Ciekłe formulacje LH |
JP5715418B2 (ja) | 2007-11-08 | 2015-05-07 | ノボ・ノルデイスク・エー/エス | インスリン誘導体 |
CN101970476B (zh) | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的胰岛素衍生物 |
EP2229407B1 (de) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
JP2009091363A (ja) | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Pthの安定化水溶液注射剤 |
WO2011003823A1 (de) | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Langsamwirkende insulinzubereitungen |
WO2011003820A1 (de) | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Hitze- und schüttelstabile insulinzubereitungen |
MY159865A (en) | 2009-07-06 | 2017-02-15 | Sanofi Aventis Deutschland | Aqueous insulin preparations containing methionine |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
TW201605489A (zh) | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素(insulin glulisine)的穩定調配物 |
-
2009
- 2009-01-06 EP EP09701358.5A patent/EP2229407B1/de active Active
- 2009-01-06 JP JP2010541743A patent/JP5694779B2/ja not_active Expired - Fee Related
- 2009-01-06 HU HUE09701358A patent/HUE030537T2/en unknown
- 2009-01-06 AU AU2009203809A patent/AU2009203809B2/en not_active Ceased
- 2009-01-06 ES ES09701358.5T patent/ES2613152T3/es active Active
- 2009-01-06 CN CN200980101962.3A patent/CN102007143B/zh not_active Expired - Fee Related
- 2009-01-06 KR KR1020107014961A patent/KR20100111682A/ko not_active Application Discontinuation
- 2009-01-06 CA CA2711749A patent/CA2711749A1/en not_active Abandoned
- 2009-01-06 PL PL09701358T patent/PL2229407T3/pl unknown
- 2009-01-06 RU RU2010133231/10A patent/RU2524423C2/ru not_active IP Right Cessation
- 2009-01-06 WO PCT/EP2009/000017 patent/WO2009087081A2/de active Application Filing
- 2009-01-06 BR BRPI0907371A patent/BRPI0907371A2/pt not_active IP Right Cessation
- 2009-01-06 NZ NZ586590A patent/NZ586590A/en not_active IP Right Cessation
- 2009-01-06 MY MYPI20102683 patent/MY152979A/en unknown
- 2009-01-06 DK DK09701358.5T patent/DK2229407T3/da active
- 2009-01-07 UY UY031596A patent/UY31596A1/es not_active Application Discontinuation
- 2009-01-07 AR ARP090100035A patent/AR070118A1/es unknown
- 2009-01-07 TW TW098100281A patent/TW200942256A/zh unknown
- 2009-01-07 CL CL2009000017A patent/CL2009000017A1/es unknown
- 2009-01-07 PA PA20098811601A patent/PA8811601A1/es unknown
- 2009-01-07 PE PE2009000009A patent/PE20091377A1/es not_active Application Discontinuation
-
2010
- 2010-06-02 ZA ZA2010/03926A patent/ZA201003926B/en unknown
- 2010-06-22 US US12/820,722 patent/US9644017B2/en not_active Expired - Fee Related
- 2010-06-25 TN TN2010000298A patent/TN2010000298A1/fr unknown
- 2010-06-28 NI NI201000114A patent/NI201000114A/es unknown
- 2010-06-30 CO CO10079133A patent/CO6311108A2/es not_active Application Discontinuation
- 2010-07-02 DO DO2010000209A patent/DOP2010000209A/es unknown
- 2010-07-05 MA MA32985A patent/MA31998B1/fr unknown
- 2010-07-06 IL IL206844A patent/IL206844A/en not_active IP Right Cessation
- 2010-07-08 EC EC2010010333A patent/ECSP10010333A/es unknown
- 2010-07-08 GT GT201000199A patent/GT201000199A/es unknown
-
2011
- 2011-04-21 HK HK11104060.4A patent/HK1149772A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2229407T3 (da) | Nye insulinderivater med ekstremt forsinket tids-/virkningsprofil | |
AU2009203810B2 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
RU2529952C2 (ru) | Новые производные инсулина с сильно замедленным профилем время/действие | |
JP5325778B2 (ja) | アミド化されたグラルギンインスリン | |
US8399407B2 (en) | Non-standard insulin analogues | |
JP2011526886A (ja) | 持効型活性を有する新規インスリン類似体 | |
KR20110061552A (ko) | 할로겐 안정화된 인슐린 | |
US20150299286A1 (en) | Glutamic acid-stabilized insulin analogues | |
EP3883957A1 (en) | Single-chain insulin analogues with poly-alanine c-domain sub-segments | |
DE102008025008A1 (de) | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil | |
Zhang et al. | Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1 | |
DE102008025007A1 (de) | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |